收费全文 | 10134篇 |
免费 | 904篇 |
国内免费 | 873篇 |
2024年 | 17篇 |
2023年 | 146篇 |
2022年 | 313篇 |
2021年 | 605篇 |
2020年 | 422篇 |
2019年 | 448篇 |
2018年 | 437篇 |
2017年 | 316篇 |
2016年 | 455篇 |
2015年 | 627篇 |
2014年 | 811篇 |
2013年 | 777篇 |
2012年 | 967篇 |
2011年 | 801篇 |
2010年 | 554篇 |
2009年 | 439篇 |
2008年 | 479篇 |
2007年 | 513篇 |
2006年 | 417篇 |
2005年 | 350篇 |
2004年 | 308篇 |
2003年 | 241篇 |
2002年 | 213篇 |
2001年 | 176篇 |
2000年 | 156篇 |
1999年 | 154篇 |
1998年 | 73篇 |
1997年 | 73篇 |
1996年 | 75篇 |
1995年 | 53篇 |
1994年 | 67篇 |
1993年 | 54篇 |
1992年 | 75篇 |
1991年 | 59篇 |
1990年 | 39篇 |
1989年 | 51篇 |
1988年 | 29篇 |
1987年 | 33篇 |
1986年 | 24篇 |
1985年 | 26篇 |
1984年 | 8篇 |
1983年 | 13篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1978年 | 1篇 |
1970年 | 1篇 |
Background
Although high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) has been confirmed to result in longer remission time than conventional chemotherapy, multiple myeloma (MM) remains incurable. Post-ASCT maintenance is considered as a strategy for obtaining durable remissions and preventing tumor progression. Randomized controlled trials (RCTs) studying maintenance therapy with immunomodulatory drugs (IMiDs) after ASCT have shown some valuable survival improvements. This meta-analysis of RCTs therefore assesses the effect of post-ASCT IMiDs maintenance on MM patients.Methods
We performed a meta-analysis to evaluate the impact of IMiDs (thalidomide or lenalidomide) as post-ASCT maintenance therapy on the survival of newly diagnosed MM patients. The outcomes for this meta-analysis were progression-free survival (PFS) and overall survival (OS).Results
Eight RCTs enrolling 3514 patients were included for analysis. An obvious improvement in Os (hazard ratio [HR] 0.75) and a significant PFS advantage (HR 0.58) with post-ASCT IMiDs maintenance was revealed. Thalidomide maintenance after ASCT can result in significant benefit in Os (HR 0.72), particularly combined with corticosteroids (HR 0.66).Conclusions
MM patients after ASCT have a significant overall survival benefit with IMiDs maintenance. IMiDs maintenance was justified for MM patients who received HDT with ASCT. 相似文献The specific and high-level expression of 1Ax1 is determined by different promoter regions. HMW-GS synthesis occurs in aleurone layer cells. Heterologous proteins can be stored in protein bodies.
AbstractHigh-molecular-weight glutenin subunit (HMW-GS) is highly expressed in the endosperm of wheat and relative species, where their expression level and allelic variation affect the bread-making quality and nutrient quality of flour. However, the mechanism regulating HMW-GS expression remains elusive. In this study, we analyzed the distribution of cis-acting elements in the 2659-bp promoter region of the HMW-GS gene 1Ax1, which can be divided into five element-enriched regions. Fragments derived from progressive 5′ deletions were used to drive GUS gene expression in transgenic wheat, which was confirmed in aleurone layer cells, inner starchy endosperm cells, starchy endosperm transfer cells, and aleurone transfer cells by histochemical staining. The promoter region ranging from ??297 to ??1 was responsible for tissue-specific expression, while fragments from ??1724 to ??618 and from ??618 to ??297 were responsible for high-level expression. Under the control of the 1Ax1 promoter, heterologous protein could be stored in the form of protein bodies in inner starchy endosperm cells, even without a special location signal. Our findings not only deepen our understanding of glutenin expression regulation, trafficking, and accumulation but also provide a strategy for the utilization of wheat endosperm as a bioreactor for the production of nutrients and metabolic products.
相似文献